NOT FOR DISTRIBUTION
Header cover image

CSPC Innovation Pharmaceutical

Market Cap

CN¥7.4b

Last Updated

2021/04/17 09:08 UTC

Data Sources

Company Financials

Executive Summary

CSPC Innovation Pharmaceutical Co., Ltd. manufactures and sells caffeine, and vitamin C health supplement and beverage products. More Details


Snowflake Analysis

Flawless balance sheet with acceptable track record.

Share Price & News

How has CSPC Innovation Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 300765 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 300765's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-2.2%

300765

-2.8%

CN Pharmaceuticals

-0.8%

CN Market


1 Year Return

-30.4%

300765

10.4%

CN Pharmaceuticals

25.0%

CN Market

Return vs Industry: 300765 underperformed the CN Pharmaceuticals industry which returned 10.4% over the past year.

Return vs Market: 300765 underperformed the CN Market which returned 25% over the past year.


Shareholder returns

300765IndustryMarket
7 Day-2.2%-2.8%-0.8%
30 Day-5.1%1.0%-0.08%
90 Day0.3%-5.1%-5.3%
1 Year-30.2%-30.4%11.5%10.4%27.0%25.0%
3 Yearn/a25.2%20.8%29.1%22.8%
5 Yearn/a46.5%38.7%30.5%21.7%

Long-Term Price Volatility Vs. Market

How volatile is CSPC Innovation Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CSPC Innovation Pharmaceutical undervalued compared to its fair value and its price relative to the market?

24.58x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 300765 (CN¥17.55) is trading above our estimate of fair value (CN¥14.42)

Significantly Below Fair Value: 300765 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 300765 is good value based on its PE Ratio (24.6x) compared to the CN Pharmaceuticals industry average (31.9x).

PE vs Market: 300765 is good value based on its PE Ratio (24.6x) compared to the CN market (33.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 300765's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 300765's PB Ratio (2.8x) is in line with the CN Pharmaceuticals industry average.


Future Growth

How is CSPC Innovation Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CSPC Innovation Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has CSPC Innovation Pharmaceutical performed over the past 5 years?

15.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 300765 has high quality earnings.

Growing Profit Margin: 300765's current net profit margins (22.8%) are higher than last year (21.8%).


Past Earnings Growth Analysis

Earnings Trend: 300765's earnings have grown by 15.8% per year over the past 5 years.

Accelerating Growth: 300765's earnings growth over the past year (9.7%) is below its 5-year average (15.8% per year).

Earnings vs Industry: 300765 earnings growth over the past year (9.7%) underperformed the Pharmaceuticals industry 10.3%.


Return on Equity

High ROE: 300765's Return on Equity (11.2%) is considered low.


Financial Health

How is CSPC Innovation Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 300765's short term assets (CN¥1.9B) exceed its short term liabilities (CN¥234.2M).

Long Term Liabilities: 300765's short term assets (CN¥1.9B) exceed its long term liabilities (CN¥33.8M).


Debt to Equity History and Analysis

Debt Level: 300765 is debt free.

Reducing Debt: 300765 has no debt compared to 5 years ago when its debt to equity ratio was 19.2%.

Debt Coverage: 300765 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 300765 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is CSPC Innovation Pharmaceutical current dividend yield, its reliability and sustainability?

0.57%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 300765's dividend (0.57%) is higher than the bottom 25% of dividend payers in the CN market (0.44%).

High Dividend: 300765's dividend (0.57%) is low compared to the top 25% of dividend payers in the CN market (1.79%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether 300765's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if 300765's dividend payments are increasing as they only just started paying a dividend.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (14%), 300765's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

CSPC Innovation Pharmaceutical has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

CSPC Innovation Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CSPC Innovation Pharmaceutical Co., Ltd.
  • Ticker: 300765
  • Exchange: SZSE
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥7.370b
  • Shares outstanding: 420.00m
  • Website: https://www.xnwpharma.net

Number of Employees


Location

  • CSPC Innovation Pharmaceutical Co., Ltd.
  • No. 36, Fuqiang Western Road
  • Luancheng County
  • Shijiazhuang
  • Hebei Province
  • 51430
  • China

Listings


Biography

CSPC Innovation Pharmaceutical Co., Ltd. manufactures and sells caffeine, and vitamin C health supplement and beverage products. The company is based in Shijiazhuang, China. CSPC Innovation Pharmaceutical ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/17 09:08
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.